Drugs / MMV367
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05979207 | Aug → Oct 2023 | Plasmodium falciparum malaria, parasitemia | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT05507970 | Jul 2022 → Jan 2023 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMV367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507970 ↗ |
| Route | Oral | “single-dose oral administration of MMV367” NCT05507970 ↗ |